drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Patient-derived T cells genetically engineered to express an anti-CD5 chimeric antigen receptor that binds CD5 on malignant T cells and activates CAR-mediated cytotoxicity (CD3zeta/costimulatory signaling), leading to killing of CD5+ tumor cells with expected on-target depletion of normal CD5+ T cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous patient T cells are genetically engineered to express a CD5-directed chimeric antigen receptor. Upon binding CD5 on malignant T cells, the CAR transmits activation signals (CD3ΞΆ with costimulatory domains), triggering T-cell cytotoxicity (perforin/granzyme) and elimination of CD5+ tumor cells, with expected on-target depletion of normal CD5+ T cells.
drug_name
Autologous CD5 CAR T cells
nct_id_drug_ref
NCT06316856